440 related articles for article (PubMed ID: 30563089)
1. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.
Pramanik KC; Makena MR; Bhowmick K; Pandey MK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089
[TBL] [Abstract][Full Text] [Related]
2. Critical role of NF-κB in pancreatic cancer.
Prabhu L; Mundade R; Korc M; Loehrer PJ; Lu T
Oncotarget; 2014 Nov; 5(22):10969-75. PubMed ID: 25473891
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
4. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma.
Ye H; Zhou Q; Zheng S; Li G; Lin Q; Wei L; Fu Z; Zhang B; Liu Y; Li Z; Chen R
Cell Death Dis; 2018 May; 9(5):453. PubMed ID: 29670110
[TBL] [Abstract][Full Text] [Related]
6. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
Geismann C; Grohmann F; Dreher A; Häsler R; Rosenstiel P; Legler K; Hauser C; Egberts JH; Sipos B; Schreiber S; Linkermann A; Hassan Z; Schneider G; Schäfer H; Arlt A
Biochim Biophys Acta Mol Cell Res; 2017 May; 1864(5):782-796. PubMed ID: 28188806
[TBL] [Abstract][Full Text] [Related]
7. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis.
Ma Q; Wu X; Wu J; Liang Z; Liu T
Int J Oncol; 2017 Oct; 51(4):1104-1114. PubMed ID: 28902358
[TBL] [Abstract][Full Text] [Related]
8. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
9. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells.
Ma Z; Vocadlo DJ; Vosseller K
J Biol Chem; 2013 May; 288(21):15121-30. PubMed ID: 23592772
[TBL] [Abstract][Full Text] [Related]
10. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression.
Kiefel H; Bondong S; Erbe-Hoffmann N; Hazin J; Riedle S; Wolf J; Pfeifer M; Arlt A; Schäfer H; Müerköster SS; Altevogt P
Oncogene; 2010 Aug; 29(34):4766-78. PubMed ID: 20543863
[TBL] [Abstract][Full Text] [Related]
11. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.
Geismann C; Grohmann F; Sebens S; Wirths G; Dreher A; Häsler R; Rosenstiel P; Hauser C; Egberts JH; Trauzold A; Schneider G; Sipos B; Zeissig S; Schreiber S; Schäfer H; Arlt A
Cell Death Dis; 2014 Oct; 5(10):e1455. PubMed ID: 25299780
[TBL] [Abstract][Full Text] [Related]
12. Dysbindin promotes pancreatic ductal adenocarcinoma metastasis by activating NF-κB/MDM2 via miR-342-3p.
Zhu D; Zheng S; Fang C; Guo X; Han D; Tang M; Fu H; Jiang M; Xie N; Nie Y; Yao X; Chen Y
Cancer Lett; 2020 May; 477():107-121. PubMed ID: 32120026
[TBL] [Abstract][Full Text] [Related]
13. NEMO/NF-κB signaling functions as a double-edged sword in PanIN formation versus progression to pancreatic cancer.
Tsesmelis M; Büttner UFG; Gerstenlauer M; Manfras U; Tsesmelis K; Du Z; Sperb N; Weissinger SE; Möller P; Barth TFE; Maier HJ; Chan LK; Wirth T
Mol Cancer; 2024 May; 23(1):103. PubMed ID: 38755681
[TBL] [Abstract][Full Text] [Related]
14. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer.
Nakashima H; Nakamura M; Yamaguchi H; Yamanaka N; Akiyoshi T; Koga K; Yamaguchi K; Tsuneyoshi M; Tanaka M; Katano M
Cancer Res; 2006 Jul; 66(14):7041-9. PubMed ID: 16849549
[TBL] [Abstract][Full Text] [Related]
16. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.
Döppler H; Panayiotou R; Reid EM; Maimo W; Bastea L; Storz P
Sci Rep; 2016 Sep; 6():33758. PubMed ID: 27649783
[TBL] [Abstract][Full Text] [Related]
17. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.
Maniati E; Bossard M; Cook N; Candido JB; Emami-Shahri N; Nedospasov SA; Balkwill FR; Tuveson DA; Hagemann T
J Clin Invest; 2011 Dec; 121(12):4685-99. PubMed ID: 22056382
[TBL] [Abstract][Full Text] [Related]
19. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis.
Yuan P; He XH; Rong YF; Cao J; Li Y; Hu YP; Liu Y; Li D; Lou W; Liu MF
Cancer Res; 2017 Jan; 77(1):100-111. PubMed ID: 27793842
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]